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Abstract 
The main physiological function of adipose-derived stromal/progenitor cells (ASC) is to 
differentiate into adipocytes. ASC are most likely localized at perivascular sites in adipose tissues 
and retain the capacity to differentiate into multiple cell types. Although cell surface markers for 
ASC have been described, there is no complete consensus on the antigen expression pattern that 
will precisely define these cells. DLK1(PREF1) is an established marker for mouse adipocyte 
progenitors which inhibits adipogenesis. This suggests that DLK1(PREF1) could be a useful 
marker to characterize human ASC. The DLK1(PREF1) status of human ASC is however 
unknown. In the present study we isolated ASC from the heterogeneous stromal vascular fraction 
of subcutaneous abdominal fat pats of adult women. These cells were selected by their plastic 
adherence and expanded to passage 5. The ASC were characterized as relatively homogenous cell 
population with the capacity to differentiate in vitro into adipocytes, chondrocytes, and osteoblasts 
and the immunophenotype CD105+/CD90+/CD34+/CD31-/FABP4-. The ASC were positive for 
DLK1(PREF1) which was well expressed in proliferating and density arrested cells but 
downregulated in the course of adipogenic differentiation. To investigate whether DLK1(PREF1) 
plays a role in the regulation of adipogenesis in these cells RNAi-mediated knockdown 
experiments were conducted. Knockdown of DLK1(PREF1) in differentiating ASC resulted in a 
significant increase of the expression of the adipogenic key regulator PPARγ2 and of the terminal 
adipogenic differentiation marker FABP4. We conclude that DLK1(PREF1) is well expressed in 
human ASC and acts as a negative regulator of adipogenesis. Moreover, DLK1(PREF1) could be 
a useful marker contributing to the characterization of human ASC. 
 
3 
 
 
Key words 
Human adipose-derived stromal cells, Adipogenesis, ASC, CD31, CD34, CD90, CD105, 
DLK1(PREF1), FABP4, PPAR2. 
 
 
4 
 
1.1 Introduction 
White adipose tissues are the primary triglyceride/energy storages of the body acting as metabolic 
regulator in glucose homeostasis and lipid metabolism [1], and as endocrine organ [2]. The main 
cell type in fat tissues fulfilling these functions is the mature adipocyte. In adult humans 
approximately 10 % of fat cells in adipose depots are renewed annually [3], and surgical removal 
of fat tissue in rodents induces compensatory recovery [4]. This indicates a high demand of 
progenitor cells for renewal and, hence, maintenance of adipose tissue functions. In fact, the 
number of adipocyte progenitors in a given fat tissue can vary between 15–40 % of the cell 
population dependent on the tissue type, localization in the body, physiological conditions, and 
age [2, 5, 6]. 
White adipocyte progenitor cells were identified in vivo [7], and evidence provided by 
several studies indicates that these cells are responsible for regenerating adipocyte numbers in fat 
tissues [7-12]. In addition to adipocyte hypertrophy, an increased proliferation and adipogenic 
differentiation of ASC also contributes to the adipose tissue growth that is characteristic for 
obesity [12-14]. ASC reside most likely at perivascular sites in adipose tissues [15-17]. The 
number of intermediate stages between adipose progenitors and mature adipocytes is uncertain but 
once committed, ASC can enter an adipocyte differentiation program (adipogenesis) to acquire 
their specific functions as adipocytes [18-20]. Adipogenesis in human ASC involves growth 
arrest, early and terminal differentiation, including morphological changes, lipid accumulation 
and the expression of fat cell specific genes, for example fatty acid binding protein-4 (FABP4) 
and adipokines, such as leptin and adiponectin. The stages of adipocyte differentiation are 
orchestrated by a transcriptional cascade involving adipogenic keyfactors, such as the nuclear 
receptor peroxisome proliferator-activated receptor-γ2 (PPARγ2) and members of the 
CCAAT/enhancer-binding protein (C/EBP) family [18, 20]. 
 
5 
 
Adipose-derived stromal cells (ASC) are most frequently isolated by collagenase digestion 
of white adipose tissue, yielding a stromal vascular fraction (SVF) which contains a mixture of 
heterogeneous cell types that are further purified by differential centrifugation, plating and plastic 
adherence [10, 11, 21]. It has been shown that a single adherent cell derived from the SVF can be 
expanded generating a daughter cell population with multipotent differentiation capacity, defined 
as an adult stem cell [21, 22]. As ASC possess no unique morphological characteristics great 
efforts are made to characterize this cell type by specific marker proteins. Although in many 
studies specific pattern of cellular surface markers were assigned to human ASC comprising the 
combination CD90+/CD105+/CD34+/CD31- [15, 21, 23-28], there is no complete consensus on the 
antigen expression pattern that will precisely define human ASC. Moreover, evidence was 
presented that the immunophenotype of ASC can change during expansion in cell culture, likely 
influenced by adherence to plastic culture dishes, and proliferation in medium with high 
concentrations of fetal bovine serum (FBS), that contains variable and undefined factors 
influencing proliferation, differentiation and survival of adult stem cells [21, 28, 29]. 
Delta-like protein 1/Preadipocyte factor-1 (DLK1/PREF1), which was originally identified 
as an inhibitor of adipogenesis in the murine preadipocyte cell line NIH 3T3-L1 [30], is used as 
preadipocyte marker [7, 17, 30-32]. Similar to Notch, DLK1(PREF1) is an epidermal growth 
factor repeat containing transmembrane protein that is proteolytically converted at the 
extracellular domain to generate a physiologically active soluble form that inhibits adipocyte 
differentiation [33]. Adipocyte progenitors are the sole cell type expressing DLK1(PREF1) in 
mouse adipose tissues. DLK1(PREF1) knockout mice show accelerated fat deposition, whereas 
mice overexpressing DLK1(PREF1) in adipose tissue exhibit decreased fat mass [12, 33-36]. 
DLK1(PREF1) was shown to play a role  in the regulation of cell commitment and differentiation 
in murine multipotent mesenchymal cells, regulating fat mass and bone mass formation in vivo 
[34, 36-39]. DLK1(PREF1) can also stimulate bone resorption in mice [38]. DLK1(PREF1) 
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suppresses C/EBP and C/EBP gene expression in mouse preadipocytes which leads to 
prevention of adipogenesis [37]. Moreover, DLK1(PREF1) can direct murine multipotent 
mesenchymal cells to the chondrogenic lineage but it inhibits differentiation into osteoblasts as 
well as chondrocytes [37, 40, 41]. DLK1(PREF1) was also shown to be expressed in human bone 
marrow-derived (BM) mesenchymal stem cells (MSC), but at relatively low levels [38, 42-44]. It 
keeps these cells in an undifferentiated state and regulates their differentiation into osteoblasts or 
adipocytes, at least in part by influencing their microenvironment composition [38, 42-44]. Low 
expression of DLK1(PREF1) was also found in human cord blood (CB) MSC correlating with 
strong adipogenic differentiation [45]. Moreover, DLK1(PREF1) overexpression inhibits 
adipogenesis as well as osteogenesis in CB MSC [45]. Together these data suggest that 
DLK1(PREF1) is an important regulator of mesenchymal stem cell differentiation. Thus 
DLK1(PREF1) could be a useful marker to characterize human ASC, however, the 
DLK1(PREF1) status of these cells is unknown.  
In the present study, we isolated defined populations of ASC from human abdominal 
subcutaneous fat tissue derived from 4 different women. The immunophenotype and the in vitro 
differentiation capacity of these cells was analysed after expansion in medium with low 
concentrations of FBS until passage 5. Moreover, the significance of DLK1(PREF1) for 
adipogenic differentiation of these cells was studied. 
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1.2 Material and methods 
1.2.1 Subjects 
Subcutaneous adipose tissue pads (~100 g wet weight) were obtained by incision from four 
women undergoing elective plastic abdominal surgery. [46, 47] The age of the donors was 
between 30 and 47 years. The body mass index of the subjects was between 22 – 27 kg/m2. All 
participants gave their informed written consent, and the protocol was approved by the ethical 
committee of Innsbruck Medical University, Austria. 
 
1.2.2 Isolation of human adipose-derived stem cells 
The adipose precursor cells were isolated essentially as described [10, 48]. Immediately after 
surgery adipose tissue biopsies were transferred into sterile serum-free ASC medium (DMEM/F-
12 medium (1:1) with HEPES and L-Glutamine (Gibco, Vienna, Austria), supplemented with 
33µM biotin, 17µM pantothenate and 12.5μg/ml gentamicin) and kept at 4°C for 1-3 hours before 
sterile processing in a laminar flow sterile work bench class II. After rinsing with PBS fibrous 
material and blood vessels were dissected. The tissue was cut into pieces (~ 1-2 mg) and digested 
in digestion buffer (PBS containing 200U/ml collagenase (CLS Type I, Worthington Biochemical 
Corp., Lakewood, NJ) and 2% w/v BSA) under stirring for 60 min at 37°C and 450 rpm; 1 mg 
adipose tissue/3 ml digestion buffer. The dispersed tissue was centrifuged for 10 min at 200 RCF. 
The floating adipocytes were aspirated and the sedimented stromal-vascular fraction (SVF) was 
suspended in erythrocyte lysis buffer (0.155 M NH4CI, 5.7 mM K2HPO4, 0.1 mM EDTA, pH 7.3) 
and incubated for 10 min at room temperature. To remove tissue debris the cell suspension was 
filtered through a nylon mesh (pore size 100 μm). After another centrifugation step (10 min at 200 
RCF) the pelletized SVF was suspended in ASC medium supplemented with 10% FBS (Gibco, 
Vienna, Austria), and filtered through a 35µm mesh to remove residual cell aggregates. The 
pelletized SVF was composed of single cells. Aliquots of cells were inoculated at a density of 
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70,000/cm2 into 6-well plates. After 16 h of cell attachment, cells were washed with ASC medium 
to remove non-adhering material, mainly white blood cells and cell debris. Thereafter the almost 
confluent cells were maintained for 6 days in ASC medium without FBS. The medium was 
changed every second day. This led to the elimination of all non-adherent cells. The remaining 
cell population was referred to as the adipose-derived stromal cell (ASC) fraction which was used 
for further studies. This cell population contains an enriched population of adipose 
stem/progenitor cells although most likely not all of the cells are stem cells, as defined by rigorous 
criteria. 
 
1.2.3 Cell culture 
The ASC were expanded essentially as described [49]. Briefly the cells were washed with PBS 
and trypsinized using 0.5% trypsin-EDTA 1x (Gibco, Vienna, Austria). Trypsin was removed by 
centrifugation at 300 RCF for 5 min and the cells seeded in a density of 5000 cells/cm2 in ASC 
medium plus 10% FBS and maintained at 37°C with 5% CO2. 16h later the medium was replaced 
by PM4 medium (ASC medium containing 2.5% FBS, 10ng/ml EGF, 1ng/ml bFGF, 500ng/ml 
Insulin) [49]. ASC were passaged at a ratio of 1:2, medium was changed every third day and the 
cells were grown to 70% confluence before splitting. Population doublings (PDL) were calculated 
using the following equation: 1 PDL = Log10(N/N0) x 3.33 (N = number of cells at the end of a 
passage, N0 = number of cells that were seeded at the beginning of a passage). For storage cells 
were pelleted as described above, diluted in cryomedium (DMEM/F-12 medium (1:1) (1x) with 
HEPES and L-Glutamine (Gibco, Vienna, Austria), with 20% FBS and 7.5 % DMSO), at a 
density of 106 cells/ml, slowly brought to -80°C and then stored in frozen nitrogen. After thawing 
cryomedium was immediately removed by centrifugation. 
 
1.2.4 Adipogenic differentiation  
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For the induction of adipogenesis the ASC were seeded at a density of 10,000 cells/cm2 and 
grown till confluence for 6 days in PM4 medium. After a resting period of 48 hours in ASC 
medium adipogenesis was induced using differentiation medium, composed of 0.2 M insulin 
(Roche, Vienna, Austria), 0.5mM IBMX, 0.25µM dexamethasone, 2.5 % FBS, 10µg/ml 
transferrin (Sigma Vienna, Austria) in ASC medium. After day 3 of differentiation the medium 
was changed and the cells were cultivated in differentiation medium without IBMX. For 
visualization of lipid droplets cells were fixed with 4% paraformaldehyde in PBS for 1h and 
stained with 0,3 % OilRedO (Sigma, Vienna, Austria) in isopropanol/water (60:40) for 1h. Final 
washing was carried out twice with distilled water.  
 
1.2.5 Osteogenic differentiation  
For induction of osteogenesis ASC were seeded at a density of 20,000 cells/cm2 in ACS medium 
plus 10 % FBS. After 16h medium was replaced by osteogenic differentiation medium 
(STEMPRO Osteocyte/Chondrocyte Differentiation Basal Medium combined with STEMPRO 
Osteogenesis Supplement (Gibco, Vienna, Asutria)) and renewed every second day. After 21 days 
osteoblasts are fixed with 4% paraformaldehyde in PBS for 30 minutes, washed with PBS and 
stained with 2% Alizarin-Red-S (Sigma, Vienna Austria) for 20 minutes. Final washing procedure 
was carried out two times with PBS pH 4.0. 
 
1.2.6 Chondrogenic differentiation  
The ASC were seeded in 5 separate 5µl droplets of ASC medium plus 10% FBS, each containing 
16,000 cells per 9.6 cm2 well. After 2 hours each well was carefully filled with 2 ml of 
STEMPRO Osteocyte/Chondrocyte Differentiation Basal Medium combined with STEMPRO 
Chondrogenesis  Supplement (Gibco, Vienna, Austria). Medium was replaced every second day. 
After 21 days chondrocytes were fixed with 4% paraformaldehyde (Sigma) in PBS for 30 
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minutes, washed with PBS and stained with 1% Alcian-Blue 8GX (Molekula, Taufkirchen, 
Germany) in 0.1N HCl for 30 minutes. Final washing was done three times with 0.1N HCl and 
two times with distilled water.  
 
1.2.7 Cultivation of human foreskin fibroblasts, HUVEC, and PBMCs  
Human foreskin fibroblasts and human umbilical vein endothelial cells (HUVEC) were isolated 
and cultivated essentially as described [50]. PBMCs were prepared and cultivated as described 
[51].  
 
1.2.8 Quantitative RT-PCR 
Total RNA was isolated with the RNeasy Micro Kit (Qiagen, Hilden, Germany), and cDNA 
synthesis was performed with the First Strand cDNA Synthesis Kit (Fermentas, St.Leon-Rot, 
Germany). Quantitative expression analysis was performed using the LightCycler® 480 Real-
Time PCR System (Roche, Vienna, Austria). The mRNA quantification was performed using 
actin or TATA binding protein (TBP) for normalization. Primers: The sequences, genbank 
accession numbers, and the base numbers of the primers within the sequence are indicated in table 
1. 
 
1.2.9 Immuofluorescence experiments 
Immunofluorescence experiments were conducted as described [52]. Briefly, cells were fixed with 
4% (w/v) PFA/1×PBS, permeabilized with 0.1% (w/v) Na-Citrate/0.2% (v/v) Triton-X-100, 
blocked with 1×PBS/1%BSA and incubated for 1 h at 37 °C with primary antibodies in 1× 
PBS/1%BSA. After washing in 1×PBS/1%BSA and staining with secondary IgGs, 
(DAKOCytomation, Hamburg), cells were processed for indirect immunofluorescence 
microscopy and viewed using a confocal laser-scanning system. Antibodies: Goat anti human 
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endoglin/CD105, C-20, (Santa Cruz, California, # sc-19790), mouse anti human CD31 (BD 
Pharmingen, Heidelberg, # 555446),  mouse anti human CD34 (BD Pharmingen, Heidelberg, 
#555822), mouse anti human CD90 (BD Pharmingen, Heidelberg, #555596), rat anti 
mouse/human F4/80 (Biolegend, San Diego, #122615), goat anti human FABP4 C-15 (Santa 
Cruz, California, # sc-18661), mouse anti human MTS1/FSP1, X9-7 (Santa Cruz, California #sc-
100784), mouse anti human DLK1 / PREF1 (R&D, Minneapolis, #MAB1144), mouse anti human 
VWF [F8/86] (Abcam, Cambridge ab855), mouse anti human calnexin, clone 37 (BD 
Pharmingen, Heidelberg, #610523), mouse anti rat GM130, clone 35 (BD Pharmingen, 
Heidelberg, #610822), anti mouse/rabbit/goat IgG FITC labeled (DAKOCytomation, Hamburg), 
anti mouse/goat IgG Alexa Fluor 555nm/488nm (Invitrogen, Lofer); TO-PRO-3 served as nucleic 
acid dye (Invitrogen, Lofer). 
 
1.2.10 Westernblot analysis  
Cell lysates were prepared in sample buffer (2% SDS, 6% glycerine, 0,1M DTT, 0,5% brom-
phenol-blue, 62.5mM Tris-HCl pH 6.8), separated by SDS-PAGE and western blot analysis was 
performed essentially as described [53]. Antibodies: Mouse anti human βactin, clone AC-15 
(Sigma, Missouri, #A5441), goat anti human FABP4, clone C-15, (Santa Cruz, California, # sc-
18661), rat anti human DLK1 (PREF1) (AdipoGen, San Diego, # AG-25A-0091), anti mouse IgG 
HRP conjugate (Promega, Mannheim #W420B), donkey anti goat IgG-HRP (Promega, 
Mannheim #V805A), rabbit anti-rat IgG HRP (Dako Cytomation, Hamburg, #P0450). 
 
1.2.11 Plasmids/ Lentiviruses 
pMD2.G, psPAX2 and pLKO.1 TRC (sh control vector) (D. Trono # 12259, D. Trono #12260, 
Root #10879, Addgene, Cambridge, USA). The DLK1(PREF1) overexpressing lentivirus, 
pLentiDLK1(PREF1), was constructed inserting the full length human DLK1(PREF1) cDNA 
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from pCMV6-AC-DLK1(PREF1), NM_003836 (SC320741) (Origene, Rockville) into 
pLenti6/DEST (Invitrogen, Lofer, Austria) using the Gateway Lentiviral Cloning System, 
Invitrogen, Lofer, Austria. The correct DLK1(PREF1) cDNA sequence in plentiDLK1(PREF1) 
was verified by sequencing. DLK1(PREF1) shRNA lentiviruses: sh#2 and sh#3 
(TRCN0000055979 and TRCN0000055980 of the shRNA set #RHS4533 for NM_003836, Open 
Biosystems, Vienna). 
 
1.2.12 Retroviral gene expression system 
5 different pLKO.1 lentiviral DLK1(PREF1) shRNA vectors for accession NM_003836 
(#RHS4533, Open Biosystems, Vienna) were used for lentiviral particle production employing the 
ViraPowerTM Lentiviral Expression System (Invitrogen, Lofer, Austria) and a second-generation 
system provided by the Trono lab (Addgene, Cambridge, USA). The same procedure was used to 
generate virus particles of the DLK1(PREF1) overexpressing lentivirus pLentiDLK1(PREF1). 
The purified viral particles were stored at -80°C. For viral infection, 900,000 ASC were seeded in 
a 75-cm2 bottle, with 8 ml medium, 6 µg/ml polybrene and virus particles at a multiplicity of 
infection (MOI) of 1:4. After 24 h, the medium was changed, and the cells were grown for another 
48 h before they were trypsinized and seeded at 10,000 cells/cm2 for subsequent differentiation. 
The efficiency of the DLK1(PREF1) knockdown was measured by qRT-PCR and Western blot 
analysis 4 days after infection or later. The most efficient knockdown clones for DLK1(PREF1) 
(sh#2 and sh#3) which were identified by qRT-PCR and Western blotting were used for further 
experiments. 
 
1.2.13 Flow cytometry analysis 
SVF and trypsinized early passage ASC, 250,000 cells per sample, were simultaneously fixed and 
permeabilized using BD Cytofix/Cytoperm™ solution to prepare the cells for intracellular and 
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surface marker staining. The cells were subjected to immunofluorescence staining using a panel of 
directly conjugated mouse monoclonal antibodies: CD31-FITC-A (WM59) #557508, CD34-PE-
Cy7A (581) #560710, CD90-PE-A (5E10) #555596, CD105-PerCP-Cy5-5-A (266) #560819; BD 
Pharmingen, Heidelberg) For DLK1/PREF1 immunofluorescence staining a rat monoclonal anti 
human DLK1/PREF1 antibody (AG-25A-0091, Adipogen, San Diego) was used in combination 
with an anti-rat-APC-A antibody (BD Pharmingen, Heidelberg, #551019). The labeled cells were 
measured using a FACSCanto II (BD Biosciences) and the data were analyzed using the 
FACSDiva software (BD Biosciences). 
 
 
14 
 
1.3 Results 
1.3.1 Immunophenotype of human ASC derived from abdominal subcutaneous fat pads 
Fresh human abdominal subcutaneous fat pads obtained by surgical resection were processed for 
the isolation of the stromal-vascular cell fraction (SVF) (Supplemental Fig. 1A), essentially as 
described [10, 28, 48]. The heterogeneous SVF was maintained in ASC medium with 10% FBS 
for 16 hours to allow cell attachment on plastic cell culture dishes (passage -1, P-1). Subsequently 
the cells were kept in serum-free ASC medium for 6 days. Contaminating non adherent cells were 
removed by changing the medium. The resulting cell fraction was referred to as ASC passage 0 
(P0). Under these conditions 230,000 +/- 100,000 SVF cells were isolated per gram fat tissue and 
19 % +/- 6 % were recovered from the SVF as adherent ASC at P0. It should be considered that 
the cell yield per mg fat depends on the donor tissue. The ASC were expanded until passage 5 in 
PM4 medium [49] containing low concentrations of Insulin, EGF, FGF and 2.5% FBS in a 20% 
O2/5% CO2 atmosphere. Under these conditions the ASC proliferated robustly with a doubling 
time of ~ 60 hours. To identify potential heterogeneous cells, the adherent cell fraction was 
stained with antibodies against fibroblast specific protein 1 (FSP1), F4/80(EMR1), a macrophage 
marker, and von Willebrand factor (VWF), an endothelial cell specific protein (Supplemental Fig. 
1B). The analysis of 10,000 cells for each marker by indirect immunofluorescence analysis 
viewed through a confocal laser-scanning microscope demonstrated that the vast majority of the 
ASC culture was free of fibroblasts, macrophages and endothelial cells. To underline these results, 
qRT-PCR was performed to show the mRNA expression of FSP1, F4/80, and VWF. F4/80 
mRNA was not detectable in ASC compared to PBMC and monocytes (Supplemental Fig. 1C, 
upper panel). This was also found for VWF mRNA compared with HUVEC (Supplemental 
Fig.1C, middle panel). FSP1 mRNA was also relatively low in ASC relative to human foreskin 
fibroblasts (Supplemental Fig. 1C, lower panel). These data indicate that after isolation from the 
adipose SVF, 6 days FBS starvation on plastic cell culture dishes, and expansion until passage 5 
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in PM4 medium, we obtained a homogeneous cell population concerning the examined markers, 
although it is likely that there are other markers that are not homogeneously expressed. This cell 
population was referred to as the adipose-derived stromal cell (ASC) fraction which was used for 
further studies. This cell population contains an enriched population of adipose stem/progenitor 
cells but most likely not all of the cells are stem cells, as defined by rigorous criteria. 
The population of ASC was further characterized in indirect immunofluorescence 
experiments by antibodies against established marker proteins used as major lineage determinant 
proteins (Supplemental Fig. 1D). CD90 (Thy1) and CD105 (endoglin) are known as mesenchymal 
stem cell (MSC) markers [54] which are also expressed in HUVEC cells [55] (Supplemental Fig. 
1D). CD34 is not expressed in MSCs [56], but in both hematopoietic [57] and endothelial [58] 
progenitors (Supplemental Fig. 1D). CD31 (PECAM-1) is a marker for endothelial cells [54, 59] 
(Supplemental Fig. 1D). Our ASC highly expressed CD90, CD105 and CD34 but not CD31 (Fig. 
1A), as shown previously [23]. We found that a considerable proportion of CD105 was not 
localized on the cell surface but in intracellular structures. To identify these structures we co-
stained the ASC with antibodies against CD105 in combination with antibodies against either 
calnexin, a protein of the endoplasmatic reticulum (ER), or GM130, a protein of the Golgi 
apparatus. Confocal microscopy analysis demonstrated that considerable proportions of CD105 
co-localized with structures of the Golgi apparatus as well as the ER (Fig. 1B). DLK1(PREF1) is 
an established marker for mouse adipocyte progenitors [33]. The DLK1(PREF1) status of human 
ASC is unknown. Indirect immunofluorescence experiments demonstrated that all cells in the 
ASC population at passage 5 stained strongly positive for DLK1(PREF1) (Fig. 1A). As indicated 
by their specific marker composition, the ASC vary significantly from MSC, HSC, HUVEC, 
macrophages and fibroblasts. The immunofluorescence microscopy analysis of 10,000 cells for 
each marker indicated a homogeneity of the DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31- ASC 
fraction of > 99.8 %. To corroborate these data and to demonstrate the presence of 
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DLK1(PREF1), CD105, CD90, and CD34 and the absence of CD31 in the same cell, passage 5 
ASC were subjected to multi-parameter detection FACS analysis. We found that the vast majority 
of the cells was in fact DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31- (Fig. 1C).  
Since DLK1(PREF1) was identified as novel marker protein for human ASC it was 
interesting to monitor the purification of DLK1(PREF1) positive cells during enrichment of the 
ASC from the SVF and sub cultivation to passage 6 by FACS analysis (Fig. 1D, upper panel). In 
the SVF we detected 41.1 (± 3,6) % DLK1(PREF1) positive cells. After attachment of the ASC 
on plastic cell culture dishes (passage -1) 82.3 (± 1.6) % of the cell population stained positive for 
DLK1(PREF1). At passage 0, we measured 98.5 (± 0.3) % DLK1(PREF1) positive cells and at 
passage 1, 99.1 (± 0.2) % of the cells were DLK1(PREF1) positive. At passage 4 and 6 the 
number of DLK1(PREF1) positive cells was 100 %. The enrichment of DLK1(PREF1) expressing 
cells was also monitored by indirect immunofluorescence microscopy analysis (Fig. 1D, lower 
panel). Similar to the results of the FACS analysis we counted ~ 43 % DLK1(PREF1) positive 
cells in the SVF; ~ 82 % in passage -1, ~ 98 % in passage 0 and ~ 99 % in passage 1. Thus almost 
all passage 0 cells of the human ASC population were positive for DLK1(PREF1) and the 
expression of this protein remained high at later passages. To follow up the enrichment of the 
ASC population from the SVF we also analysed the expression of lineage determinant genes by 
qRT-PCR in the cell mixture of the SVF and the isolated ASC. We found a 2.5 fold increase in 
the CD90 expression (Fig. 1E), suggesting that CD90+ stem cells are enriched. In contrary, CD31 
mRNA expression was 3 times reduced in the ASC population (Fig. 1E), most likely reflecting the 
removal of floating endothelial cells. 
To determine the amount of adipocyte committed and/or differentiated cells in the ASC 
fraction the expression levels of the adipogenic differentiation marker FABP4 was measured (Fig. 
1F). FABP4 mRNA was not detectable in the ASC fraction, suggesting that adipoyctes were 
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removed during purification. In summary, the isolated ASC were characterized as 
DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31-/FABP4- cells. We obtained similar results with 
ASC populations isolated from four different women with an age between 30 and 47 years. 
1.3.2 DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31-/FABP4- human ASC possess 
multipotent differentiation capacity in in vitro assays 
Tissue-specific stem cells possess the capability to differentiate into various lineages [11, 48, 54, 
56, 60]. To get a better insight into the potential of the ASC population to differentiate into 
adipocytes, adipogenesis was induced with a hormone cocktail containing dexamethasone, IBMX, 
insulin and 2.5 % FBS (DMI) (Fig. 2A). Confocal immunofluorescence microscopy analysis 
demonstrated that the ASC marker DLK1(PREF1) was highly expressed in proliferating (Fig. 2A, 
top panel) and to a similar extent in density-arrested ASC, which stay in the G0/G1 phase of the 
cell cycle at day 0 of differentiation (Fig. 2A, middle left panel). After 14 days of differentiation 
the DLK1(PREF1) protein was almost undetectable (Fig. 2A, bottom left panel). In contrast, the 
adipogenic differentiation marker FABP4 was not detectable at day 0 but strongly induced at day 
14 of differentiation (Fig. 2A, right panel). The strong reduction of DLK1(PREF1) and induction 
of FABP4 during differentiation was corroborated at the mRNA level by qRT-PCR (Fig. 2B) and 
by western blot analysis (Fig. 2C). qRT-PCR analysis also demonstrated that the expression of the 
adipogenic keytranscription factors PPARγ2 (Fig. 2D) and C/EBP (Fig. 2E) was strongly 
induced during adipogenesis. Moreover, two terminal adipogenic differentiation markers, the 
adipokines adiponectin and leptin, were well induced in the ASC at day 9 of differentiation (Fig. 
2F and 2G). To finally assess the ability of the ASC to differentiate in in vitro assays into other 
mesenchymal lineages, ASC were put under chondrogenic, osteogenic and adipogenic 
differentiation conditions (Fig. 2H). As expected, based on their tissue of origin, the ASC 
underwent strong adipogenic differentiation, shown by Oil RedO staining of the formed lipid 
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droplets. We detected differences in the strength of the in vitro adipogenic maturation of single 
ASC isolated from the same depot, as reflected by the difference in the quantity and size of lipid 
droplets (Fig. 2H, compare white and yellow arrows). Staining of the glucosaminoglycans in 
chondrocytes with Alcian Blue and of the osteocyte specific calcification with Alizatin Red S 
demonstrated that the ASC could differentiate in all three mesenchymal cell types in vitro. 
Although these findings warrant further studies, employing a chondrogenic assay in a pellet 
culture and an osteogenic assay best done by in vivo transplantation, they suggest that clones 
isolated from our purified cell population most likely fulfill the criteria of adult tissue-specific 
multipotent stem cells [11, 48, 54, 56, 60]. 
1.3.3 DLK1(PREF1) negatively regulates adipogenesis in human ASC 
To better understand the function of DLK1(PREF1) in human ASC biology, we studied the effect 
of DLK1(PREF1) shRNA knockdown on the adipogenic differentiation potential of ASC. 
DLK1(PREF1) was knocked down using two different shRNA constructs for DLK1(PREF1) 
mRNA, sh#2 and sh#3 (Fig. 3). A strong reduction of DLK1(PREF1) mRNA was found in sh#2- 
and sh#3-containing ASC (Fig. 3A) and DLK1(PREF1) protein was significantly reduced by both 
sh#2 and sh#3 (Fig. 3B). ASC infected with a DLK1(PREF1) overexpressing lentivirus, 
pLentiDLK1(PREF1), served as positive control (Fig. 3B). The effects of the DLK1(PREF1) 
knockdown on the induction and progression of adipogenesis were monitored by assessing the 
expression of the key adipogenic regulator PPAR2 and of the terminal adipogenic differentiation 
product FABP4. We found a significant increase in the induction of PPARγ2 and FABP4 
expression in the DLK1(PREF1) knockdown cells at day 3 of adipogenesis compared to the 
control cells (Fig. 3C). We conclude that the knockdown of DLK1(PREF1) enhances adipogenic 
differentiation in human ASC. 
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1.4 Discussion 
In the present study we isolated ASC populations from subcutaneous abdominal fat pats of 
different donors and characterized these cells by their plastic adherent properties, their 
immunophenotype, DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31-/FABP4-, and a multipotent in 
vitro differentiation potential. Moreover, we demonstrated that DLK1(PREF1) functions as 
negative regulator of adipogenic differentiation in these cells. 
 The ASC could differentiate into adipocytes, osteoblasts and chondrocytes in in vitro 
assays. The absence of the cell surface marker F4/80, VWF, and FSP1 in the ASC population 
ruled out the presence of macrophages, endothelial cells and fibroblasts. The FABP4- 
immunophenotype of the ASC demonstrated the absence of cells already committed to the 
adipogenic lineage. Subcutaneous fat has been established as a source of cultured, relatively 
homogeneous ASC and ASC fractions are used as defined cell population in clinical studies [27]. 
Although specific pattern of cellular surface markers were assigned to human ASC [21, 23-26], 
some debate over the criteria defining a human ASC remains and a consensus on minimal 
obligatory criteria for ASC has not yet been defined. In keeping with the immunophenotype 
defined by the International Society for Cell Therapy for mesenchymal stromal cells (MSCs) [61], 
the vast majority of our ASC robustly expressed the MSC markers CD90 and CD105 [54] and 
were negative for the endothelial cell marker CD31 [54, 59]. CD34, a transmembrane 
glycoprotein, is known as a marker for human hematopoietic [57] and endothelial [58] 
progenitors. In contrast to MSCs [56] our ASC stained strongly positive for CD34. This result is 
in keeping with previous studies from other research groups [15, 23, 25, 28, 62, 63]. In our ASC 
CD34 was at peak after 21 days of cultivation at passage 5 and expression remained stable even 
after passaging the ASC for 82 days until passage 15. The stable expression of CD34 in later 
passages is in contrast to a previous study showing the loss of CD34 at early ASC passages [21]. 
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However, in that study the ASC were cultivated in 10 % FBS. The employment of growth 
medium with 2.5 % FBS in our study could account for these differences. It is known that long-
term cultivation of cells in high concentration of FBS leads to changes in the proliferation and 
differentiation phenotype induced by mitogenic growth factors, survival factors and 
differentiation controlling signals  [29, 64]. This leads to changes in cell specific markers as well 
as in the terminal differentiation capacity [49]. Similar to our results a recent study by Maumas et 
al., [62] demonstrated the maintenance of the CD34 cell surface marker in ASC cultured in 2 % 
FBS and the loss of CD34  in 10 % FBS. Thus our and other studies [15, 23, 25, 28, 62] strongly 
suggest that ASC belong to an adipose tissue-SVF-derived cell type displaying a CD34+ 
immunophenotpye.  
The CD34+/CD31-/CD90+ immunophenotype of our ASC population matches with stromal 
cells showing a high adipogenic potential. These cells are predominantly detected in the outer 
adventitial ring of vessels and in close proximity to capillaries in adipose tissue in situ [15, 62], 
which may be major localizations of ASC in vivo. Another MSC marker endoglin/CD105 [61], an 
accessory receptor for TGFβ [65], was not analyzed in the study by Zimmerlin et al., [15]. In 
accordance with previous studies [24, 66] CD105 was highly expressed in our passage 5 ASC. 
Some studies found increasing expression of CD105 during early passaging of ASC in growth 
medium with 10 % FBS [21]. Similarly, human BM MSCs show higher levels of stromal markers, 
including CD105, in later stages of culture  [56]. Conflicting results came from one study using 
fluorescent activating cell sorter (FACS) analyses showing that the major source of cells in the 
SVF capable of in vitro adipogenesis was the CD105-/CD34+/CD31- fraction [25]. Another group, 
however, demonstrated that a CD34+/CD90+/CD105+ ASC fraction isolated from the SVF by 
FACS was capable of undergoing endothelial as well as adipose differentiation [63], but the 
standard "tube" assay (done with Matrigel) was not performed in this study. In addition, the cells 
were not clonal, and bona fide endothelial cells may have been present. Our indirect 
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immunofluorescence experiments based on confocal microscopy, allowing visualization of 
intracellular structures, demonstrated that CD105 was predominantly localized in the transport 
compartments of the ASC and only in a minor amount in the outer membrane. There might be 
differences in the detectability of intracellular CD105 between studies dependent on the methods 
used for cell permeabilizing, fixing and antigen detection. Nevertheless, in the present study we 
showed that CD105 was highly expressed in passage 5 ASC, as demonstrated by FACS and by 
indirect immunofluorescence experiments based on confocal microscopy. 
 We analyzed whether DLK1(PREF1), that was firstly identified as a putative marker for 
murine preadipocytes [30], could be used as additional marker to characterize human ASC. We 
found that DLK1(PREF1) is highly expressed in human ASC. The DLK1(PREF1) protein levels 
were similar in human ASC proliferating in PM4 medium and in density-arrested G0/G1-phase 
ASC. In the course of adipogenic differentiation the DLK1(PREF1) protein level declined. 
DLK1(PREF1) was almost undetectable in adipocytes 14 days after the induction of adipocyte 
differentiation. Thus DLK1(PREF1) is expressed in proliferating ASC, in density-arrested ASC, 
and most likely at early stages of adipogenic differentiation but completely downregulated in 
human adipocytes. During adipogenic differentiation of MEFs (mouse embryonic fibroblasts) the 
DLK1(PREF1) protein levels are relatively low in density arrest before differentiation, transiently 
increased at day 1 and 2, and then decreased and undetectable at day 5 after conversion into 
adipocytes [37]. Similar in adipogenesis of the preadipocyte cell line NIH 3T3 L1 the 
DLK1(PREF1) protein levels are low in density arrest before differentiation and transiently 
increase until day 2 – 3 [67]. When these cells cease clonal expansion and enter terminal 
adipogenic differentiation [20], the DLK1(PREF1) protein levels decrease but membranous forms 
of DLK1(PREF1) are detectable until day 5 [67]. Thus certain forms of DLK1(PREF1) protein 
are still present at early stages of terminal adipogenic differentiation and most likely contribute to 
adipocyte differentiation [67]. DLK1(PREF1) has been identified as a negative regulator of 
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adipocyte differentiation in mouse preadipocytes [30]. Moreover, in its active form, 
DLK1(PREF1) was shown to function in an autocrine and paracrine manner as soluble factor to 
inhibit differentiation of murine multipotent MSCs into adipocytes, osteoblasts and chondrocytes 
[37, 68]. This suggests that DLK1(PREF1) has a general role in keeping mouse precursor cells in 
an undifferentiated state. In the present study we found that DLK1(PREF1) functions as negative 
regulator of adipogenesis in human ASC. Previous studies have identified DLK1(PREF1) as 
regulator of differentiation in human BM MSCs [42, 44] and CB MSCs [45]. DLK1(PREF1) was 
used as a marker to distinguish human unrestricted somatic stem cells and CB MSC [45]. 
Moreover, DLK1(PREF1) was employed as surface marker for the isolation and differentiation of 
chondrogenic cells derived from human embryonic stem cells [41]. DLK1(PREF1) is also 
involved in additional differentiation processes in rodent cells, including haematopoiesis [69], 
pancreatic islet cell differentiation [70], Schwann cell differentiation [71], hepatic cell 
differentiation [72], and differentiation of muscle satellite cells. Moreover, DLK1(PREF1) is 
expressed in thymocytes and neuroblastoma cells [reviewed in ref. 33]. Thus DLK1(PREF1) 
should be used in combination with additional markers to distinguish ASC from MSC and other 
cell types, especially in combination with the CD34+ and CD31- immunophenotype, as considered 
earlier [12].  
Studies in mice suggest that the age, depot site and sex of the donor can influence the 
features and functionality of the derived ASC [5, 73, 74]. Clinical studies found a correlation 
between donor age and differentiation capacitiy of the given ASC [75-77]. In humans also an 
influence of the BMI [78] and fat depot origin [79, 80] on ASC features was shown. In the present 
study, we isolated ASC from subcutaneous adipose tissue pads of four different women with an 
age between 30 – 47 years and a BMI between 22 – 27 kg/m2. No differences in the analyzed cell 
surface marker patterns were found between the ASC from the abdominal subcutaneous depots of 
the different donors. Moreover, all ASC populations had a high capacity to differentiate into 
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adipocytes in vitro, as demonstrated by the formation of high levels of four terminal adipogenic 
differentiation products, FABP4, adiponectin, leptin and triglycerides. This suggests that the 
relatively small differences in age and BMI between our four donors did not account for major 
differences in these ASC features. We detected however differences in the strength of the 
adipogenic maturation at the level of single ASC isolated from the same depot. This was reflected 
by the difference in the quantity and size of lipid droplets formed 20 days after the induction of 
adipogenesis (Fig. 2H, compare white and yellow arrows). These findings are in keeping with the 
differences in the single cell FABP4 protein level (Fig. 2A, compare white and yellow arrows). 
These data suggest that there may be heterogeneity regarding the adipogenic capacity of ASC 
within the same depots. Almost all passage 5 ASC stained strongly positive for the marker 
composition DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31-/FABP4-. However, this marker 
combination cannot distinguish ASC with high or low adipogenic capacity. Evidence for 
differences between ASC populations cloned from a single human subcutaneous fat depot 
regarding the differentiation capacity was previously shown [15, 81, 82]. Common observations 
in our study were islets of strongly differentiated ASC surrounded by areas of weaker 
differentiated ASC. This could, for example, result from differences in the autocrine/paracrine 
micromilieu caused by a different cell density. Such findings could mirror the existence of 
different subtypes of ASC in subcutaneous fat depots in vivo, as discussed previously [12]. More 
studies are necessary to better understand these observations. 
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Tables 
 
Gene Accession  Number Direction Sequence 
Base 
Numbers 
βActin NM_001101 forward AGA AAA TCT GGC ACC ACA CC 332-350 reverse AGA GGC GTA CAG GGA TAG CA 500-519 
AdipoQ NM_004797 forward CCT GGT GAG AAG GGT GAG AA 268-287 reverse GTA AAG CGA ATG GGC ATG TT 463-482 
C/EBPα NM_004364 forward GCG GCG ACT TTG ACT ACC 418-435 reverse GCT TGG CTT CAT CCT CCT C 606-524 
CD31 NM_000442 forward GAG TCC TGC TGA CCC TTC TG 254-273 reverse ATC TGG TGC TGA GGC TTG AC 412-431 
CD90 NM_006288 forward GAA CCA ACT TCA CCA GCA AA 286-305 reverse ATG CCC TCA CAC TTG ACC A 436-454 
PU.1 /  
F4/80 NM_001080547 
forward CAC CCC ATC CCA GTC TTG 531-548 
reverse TCT TCT TGC TGC CTG TCT CC 712-731 
FABP4 NM_001442 forward CAG TGT GAA TGG GGA TGT GA 176-195 reverse CGT GGA AGT GAC GCC TTT 408-425 
FSP1 / 
 S100A4 NM_002961 
forward GGG CAA AGA GGG TGA CAA 129-146 
reverse CTT CCT GGG CTG CTT ATC TG 350-369 
Leptin NM_000230 forward CAC ACG CAG TCA GTC TCC TC 196-215 reverse AGG TTC TCC AGG TCG TTG G 350-368 
PPARγ2 NM_015869 forward ATG GGT GAA ACT CTG GGA GA 92-111 reverse TGG AAT GTC TTC GTA ATG TGG A 316-337 
PREF1 NM_003836 forward TGA CCA GTG CGT GAC CTC T 315-333 reverse GGC AGT CCT TTC CCG AAGT A 508-526 
TBP NM_003194 forward ATG ACC CCC ATC ACT CCT G 668-686 reverse GCA CAC CAT TTT CCC AGA AC 876-895 
VWF NM_000552 forward CGC ATC CAG CAT ACA GTG AC 1691-1710 reverse GAG GGG GTA AGG AAG TCG TC 1847-1866 
 
 
Table 1: Primer list: The sequences, genbank accession numbers, and the base numbers of the 
primers within the sequence are indicated. 
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Legend to the Figures 
 
Fig. 1: Characterization of human adipose-derived stromal cells (ASC). (A) Identification of 
ASC as DLK1(PREF1)+/CD105+/CD90+/CD34+/CD31- cells. Immunofluorescence staining of 
freshly isolated ASC (passage 5) is shown. Cells were fixed in 4% PFA, stained with primary 
antibodies against DLK1(PREF1), CD105, CD90, CD34, CD31, and FITC-conjugated secondary 
antibodies (green) and processed for immunofluorescence microscopy using a confocal laser 
scanning system. Nuclei were stained with TO-PRO-3 (red) (magnification 400x). (B) Co-
localization of CD105 with calnexin (ER protein) and GM130 (Golgi apparatus protein) in ASC. 
Immunofluorescence staining of freshly isolated ASC (passage 5) is shown. Cells were fixed in 
4% PFA, stained with a primary antibody against CD105, calnexin, and GM130 and Alexa Fluor 
488nm-conjugated (green) or Alexa Fluor 555nm-conjugated secondary antibodies (red) as 
indicated. Nuclei were stained with TO-PRO-3 (red). Merge (yellow). The stained ASC were 
processed for immunofluorescence microscopy using a confocal laser scanning system 
(magnification 1000x). (C) Characterization of ASC using multi-parameter detection FACS 
analysis. 50,000 cells were counted using a BD FACS CantoII™ flow cytometer. FACS 
histograms of passage 5 ASC simultaneously stained for CD105, CD90, CD34, CD31, and 
DLK1(PREF1) are shown. Histograms are representative of 3 independent flow cytometry 
analyses. Red histograms: unstained control; blue histograms: antibody staining. (D) Enrichment 
of DLK1(PREF1) expressing cells during purification of ASC from the SVF and sub cultivation 
until passage 6. (Upper panel) 50,000 cells from each fraction (SVF, passage P-1, P0, P1, P4 and 
P6) were analyzed for DLK1(PREF1) staining using a BD FACS CantoII™ flow cytometer. The 
percentage of DLK1(PREF1) positive cells in each fraction is shown. Three independent flow 
cytometry analyses were performed for each fraction. (Lower panel) Immunofluorescence 
staining of DLK1(PREF1) positive cells in the SVF and early passage ASC. Cells were fixed in 
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4% PFA, stained with a primary antibody against DLK1(PREF1) and FITC-conjugated secondary 
antibodies (green). Nuclei were stained with TO-PRO-3 (red). Cells were viewed by 
immunofluorescence microscopy using a confocal laser-scanning system (magnification 400x). 
For the determination of the percentage of DLK1(PREF1) positive cells a total of 300 cells were 
analyzed. (E) CD90 and CD31 mRNA expression in ASC. RNA samples of SVF and ASC cells 
were isolated and qRT-PCR analysis performed using specific primers against CD90 and CD31. 
Expression results were normalized to TATA binding protein (TBP) and induction calculated 
based on ASC values which were set to 1. The induction was calculated based on SVF values. 
Three independent qRT-PCR analyses were performed. (F) FABP4 mRNA expression in ASC. 
RNA samples of SVF and ASC cells were isolated and qRT-PCR analysis performed using 
specific primers against FABP4. Expression results were normalized to TATA binding protein 
(TBP) and induction calculated based on ASC values which were set to 1. The induction was 
calculated based on SVF values. Three independent qRT-PCR analyses were performed. 
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Fig. 2: Differentiation of ASC. ASC were freshly isolated, grown until passage 5 and used for 
differentiation. Representative results for ASC from four different donors are shown. (A) 
Immunofluorescence analysis of proliferating and density-arrest ASC at day 0 and day 14 of 
adipogenesis. Indicated proteins were stained with primary antibodies against DLK1(PREF1) and 
FABP4 and FITC-conjugated secondary antibodies (green). Nuclei were stained with TO-PRO-3 
(red) (magnification 400x). (B) DLK1(PREF1) and FABP4 mRNA levels at day 0 and day 6 of 
adipogenesis. RNA samples of ASC and control cells were isolated at the indicated days and qRT-
PCR analysis performed using specific primers against DLK1(PREF1) and FABP4. Expression 
results were normalized to TATA binding protein (TBP) and induction calculated based on ASC 
values which were set to 1. Three independent qRT-PCR analyses were performed for each 
parameter. (C) DLK1(PREF1) and FABP4 protein levels in ASC at day 0 and day 6 of 
adipogenesis. ASC lysates were separated by SDS-PAGE and analyzed by western blotting using 
antibodies against DLK1(PREF1) and FABP4. actin served as input control. (D-G) Induction of 
PPAR2 (D), C/EBP (E), adiponectin (F) and leptin (G) mRNA expression during adipogenesis. 
Differentiation was induced in ASC, mRNA isolated at the indicated days of differentiation and 
relative gene expression was analyzed by qRT-PCR. Three independent qRT-PCR analyses were 
performed for each parameter. (H) ASC were in vitro differentiated into three mesenchymal cell 
types each for 20 days. Adipocytes were stained with Oil RedO, chondrocytes with Alcian Blue 
and osteoblasts with Alizarin Red-S. All three differentiation conditions changed the morphology 
of ASC and lineage specific staining was found to be positive for each resulting cell type.  
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Fig. 3: The knockdown of DLK1(PREF1) enhances adipogenesis in human ASC. ASC were 
infected with two different lentivirus constructs expressing shRNA against DLK1(PREF1), sh#2 
and sh#3, and a mock construct (sh#Control) as a control. (A) The DLK1(PREF1) knockdown 
was analysed by qRT-PCR. Normalization was calculated relative to the mock construct. The data 
are presented as the mean +/- SD of 3 measurements, (**) p ≤ 0.01; (***) p ≤ 0.001. (B) The 
efficiency of the DLK1(PREF1) protein knockdown was measured by Western blot analysis. ASC 
infected with the DLK1(PREF1) overexpression vector, pLentiDLK1(PREF1), served as positive 
control. In lane pLentiPREF1 1/10 only 10 % of the input from lane pLentiPREF1 was loaded. 
βActin served as loading control. (C) The knockdown of DLK1(PREF1) enhances adipogenesis in 
ASC. ASC were infected with lentivirus constructs expressing shRNA against DLK1(PREF1) 
(sh#2 and sh#3) or a mock construct (sh#Control) as indicated, and adipogenesis was induced by 
adding hormone cocktail. The mRNA levels of the adipogenic regulator PPARγ2, and of the 
adipogenic differentiation marker FABP-4 were determined by qRT-PCR analysis at day 3 of 
adipogenesis. The data are presented as the mean +/- SD of 3 measurements, (*) p ≤ 0.05; (***) p 
≤ 0.001. 
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Supplemental Fig. 1: Isolation of human adipose-derived stromal cells (ASC). (A) Approach 
to isolate ASC from human subcutaneous abdominal fat tissue biopsies. SVF, stromal vascular 
fraction. ASC, adipose-derived stromal cell. (B) Immunofluorescence staining of freshly isolated 
ASC (passage 5), and, as controls, human foreskin fibroblasts (HFF), peripheral blood 
mononuclears cells (PBMC), and endothelial cells (HUVEC). Cells were fixed in 4% PFA, 
stained with primary antibodies against FSP1, F4/80(EMR1) and VWF, and FITC-conjugated 
secondary antibodies (green) and processed for immunofluorescence microscopy using a confocal 
laser scanning system. Nuclei were stained with TO-PRO-3 (red) (magnification 400x). (C) 
F4/80, VWF and FSP1 mRNA expression in ASC. RNA samples of ASC and control cells were 
isolated and qRT-PCR analysis of cell type specific genes performed using specific primers 
against F4/80, VWF and FSP1. Expression results were normalized to TATA binding protein 
(TBP) and induction calculated based on ASC values which were set to 1. Three independent 
qRT-PCR analyses were performed for each parameter. (D) Detection of CD105, CD90, CD34, 
CD31 and DLK1(PREF1) in control cells. Immunofluorescence stainings of HUVEC, 
U2OS/pLentiPREF1 (U2OS cells transiently transfected with pLentiPREF1), U2OS, CaSki, and 
Granulocytes which served as positive or negative controls for DLK1(PREF1), CD105, CD90, 
CD34, and CD31 stainings are shown as indicated. Cells were fixed in 4% PFA, stained with 
primary antibodies (anti DLK1(PREF1), CD105, CD90, CD34, CD31) and FITC-conjugated 
secondary antibodies (green) and processed for immunofluorescence microscopy using a confocal 
laser scanning system. Nuclei were stained with TO-PRO-3 (red). Only merge is shown 
(magnification 400x). 
 
 
